Menu
Not yet recruiting NCT07404657

Preliminary Assessment of an Automated Tool for Diabetic Retinopathy Screening

Observational Diabetic Retinopathy (DR)

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: automatic analysis of fundus images performed by the software tool based on artificial intelligence.
Who it may be relevant to
Registry conditions: Diabetic Retinopathy (DR). Basic parameters: from 22 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
Center list to be confirmed — check the primary protocol.
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Official title

Preliminary Assessment of iCare RETCAD as an Automated Tool for Diabetic Retinopathy Screening

Overview

This study is being done to evaluate the performance of a software that uses artificial intelligence to analyze photographs of the retina to help detect diabetic retinopathy. The study will also assess the safety of the software in combination with a fundus camera already available on the market. This software analyzes retinal photographs to detect more than mild diabetic retinopathy in adults with diabetes. The results will be compared to expert human evaluations.

Interventions

  • Device automatic analysis of fundus images performed by the software tool based on artificial intelligence
    the duration of the intervention is the analysis performed by the software tool based on fundus images acquired

Primary outcome measures

  • Number of subjects whose results provided by the automatic AI-based tool match the reading center grading for the identification of referable diabetic eye disease (more than mild DR). [Time frame: 1-day visit]
Secondary outcome measures (1)
  • percentage of eyes for which the AI-based automatic tool produced a result [Time frame: 1-day visit]

Eligibility criteria

Inclusion criteria

  • 22 years old or older
  • diabetes or diabetic retinopathy
  • understand the study information and able to sign a consent form

Exclusion criteria

  • cannot tolerate eye imaging tests
  • laser treatment or injections
  • eye surgery, except for simple cataract surgery
  • currently involved in another study
  • pregnant
  • cannot or do not want to have your eyes dilated
  • photodynamic therapy within the last 90 days

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Observational model
Case-only

Study locations

Center list to be confirmed — check the primary protocol.

Identifiers

NCT: NCT07404657 · RETCAD-PVAL

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗